Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an oral dosage form for oral use. It treats infections caused by Gram‑positive bacteria, including skin and soft‑tissue infections, community‑acquired and hospital‑acquired pneumonia, as well as MRSA and VRE infections.

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable access to quality‑assured antibiotics for diverse healthcare settings, and supporting antimicrobial stewardship programs through timely delivery and regulatory compliance.

Linezolid is an oxazolidinone antibiotic indicated for several serious bacterial infections.

- Skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, to achieve clinical cure. - Community‑acquired pneumonia: treats infection caused by susceptible Streptococcus pneumoniae and other organisms, improving respiratory outcomes. - Hospital‑acquired (nosocomial) pneumonia: used for severe pneumonia caused by resistant Gram‑positive bacteria, facilitating bacterial eradication. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides an alternative therapy for MRSA when other agents are unsuitable. - Vancomycin‑resistant Enterococcus (VRE) infections: offers activity against VRE strains, aiding infection control.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Metallic taste: altered taste sensation. - Myelosuppression (reversible): mild decrease in blood cell counts. - Rash: skin irritation or mild eruption.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Peripheral neuropathy: nerve damage causing tingling or pain. - Lactic acidosis: metabolic disturbance with high lactate. - Serotonin syndrome: risk when combined with serotonergic agents. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing linezolid, clinicians should consider several safety and handling precautions. - Hematologic monitoring: perform baseline and periodic complete blood counts to detect myelosuppression. - Renal and hepatic function: assess liver and kidney status, adjust use in severe impairment. - Serotonergic drugs: avoid concomitant use with MAO inhibitors or SSRIs due to serotonin syndrome risk. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Duration of therapy: limit to the shortest effective course to reduce toxicity. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Linezolid can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Rifampicin: may reduce linezolid plasma concentrations, decreasing effectiveness. - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, necessitating therapeutic monitoring.